History

2017
  • Genmab wins DenmarkBridge Award 2017 
  • DARZALEX® (daratumumab) receives European marketing authorization for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy
2016
  • Genmab wins award for Biotech company of the year at the Scrip Awards 2016
  • DARZALEX® (daratumumab) approved by US FDA for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy
  • Genmab wins award for Company of the year at the European Mediscience Awards 2016 
  • DARZALEX® receives European conditional marketing authorization for heavily pre-treated or double refractory multiple myeloma
  • Arzerra® approved in the U.S. for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL
  • Genmab wins award for Company of the year at the BioCapital Europe conference 2016 
  • Genmab enters commercial license agreement with Gilead for DuoBody technology
  • Arzerra® approved in the U.S. in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed CLL
2015
  • Genmab enters two immuno-oncology deals: with BioNovion and BioNTech
  • Genmab acquires antibody assets to DR5 target from iDD Biotech
  • Genmab gains license to antibody panel targeting CD19 from Bristol-Myers Squibb
  • Genmab wins award for Chief Executive Officer of the year at the European Mediscience Awards 2015
  • Rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc. 
  • Genmab enters commercial agreement with Novo Nordisk for DuoBody technology
  • MAA to European regulatory authorities for daratumumab in multiple myeloma completed by Janssen-Cilag International NV
  • DARZALEX® approved by US FDA for patients with multiple myeloma who have received at least three prior lines of therapy
  • Rights to ofatumumab transferred from GSK to Novartis
2014
  • Genmab raises DKK 998 million in an international private placement
  • Genmab enters DuoBody platform research collaboration with Eli Lilly
  • Arzerra® in combination with chlorambucil approved by US Food and Drug Administration (FDA) to treat previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate
  • Arzerra® approved for use in EU as first-line treatment for CLL in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy
2013
  • Daratumumab receives Breakthrough Therapy Designation from US FDA
  • Genmab establishes sponsored Level 1 American Depositary Receipt (ADR) Program in US
  • Genmab wins award for CEO of the year at the European Mediscience Awards 2013
  • Ofatumumab receives Breakthrough Therapy Designation from US FDA
  • Genmab wins Biotech Company of the Year at the Annual SCRIP Awards
2012
  • Enters three new DuoBody platform collaborations: Novartis, Janssen, KHK
  • Genmab enters worldwide agreement with Janssen Biotech, Inc. for daratumumab
  • HexaBody® platform unveiled
2011
  • Seattle Genetics collaboration expanded with additional product
  • Ofatumumab (Arzerra®) wins Galien prize in the Netherlands
  • DuoBody-ADC research collaboration with undisclosed pharma company
  • First full year of Arzerra sales in the EU (DKK 75 million in royalties received on EU and US sales)
2010
  • Ofatumumab (Arzerra®) is granted conditional marketing authorization in the EU to treat CLL in patients who are refractory to fludarabine and alemtuzumab
  • Genmab implements an updated three-pronged corporate strategy
  • The DuoBody® bispecific antibody technology platform is introduced
  • Genmab and GSK amend the ofatumumab collaboration agreement
  • Genmab enters collaborations with Lundbeck and Seattle Genetics
2009
  • First ever BLA for a Genmab antibody is filed for ofatumumab in CLL with GSK
  • MAA for ofatumumab in CLL is filed with GSK
  • Ofatumumab (Arzerra®) is granted accelerated approval by the FDA to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab
  • Ofatumumab (Arzerra®) is launched by GSK in the US
2008
  • Genmab and GSK report positive results from first Phase III study of ofatumumab in chronic lymphocytic leukemia (CLL)
2007
  • Genmab wins the 2007 SCRIP Biotech Company of the Year award
2006
  • Genmab raises DKK 845 million in an international private placement
  • Genmab unveils its proprietary UniBody® technology platform
  • Genmab and GlaxoSmithKline (GSK) sign a co-development and commercialization agreement for ofatumumab
2005
  • Genmab wins the 2004 Helix Award for Best international biotech company
  • Daratumumab selected as CD38 antibody candidate
2004
  • Genmab raises DKK 478 million in an international private placement
2003
  • Human antibodies generated to CD38
2002
  • Genmab announces the ofatumumab program
  • Genmab delists from the Frankfurt Stock Exchange
2001
  • Genmab enters its first major partnership, an antibody development collaboration with Roche
2000
  • Genmab IPO in Copenhagen and Frankfurt raised DKK 1.56 billion, a European biotech record
1999
  • Genmab founded in Copenhagen, Denmark